Strategic partnerships Helsinn already engages in licensing and distribution partnerships across Europe and Asia, including with Angelini Pharma, Fosun Pharma, and ESTEVE. This indicates openness to co-development and commercial collaborations that sales teams can leverage to identify new regional or product-area partnership opportunities, especially for oncology supportive care assets.

Regional expansion The group maintains a widespread 90-country commercial presence with subsidiaries in Ireland, the U.S., and China, suggesting ongoing regional expansion potential. Sales efforts can target untapped markets within Europe and Asia, leveraging existing distribution networks and licensing models to introduce or extend Helsinn’s oncology and supportive care portfolio.

Portfolio focus Core emphasis on supportive care, oncology, and dermato-oncology creates cross-selling opportunities for hospitals, cancer centers, and specialty pharmacies, particularly for products like Akynzeo and ALOXI. There is potential to bundle or co-market complementary therapies and expand utilization in peri- and post-cancer care pathways.

Governance & ethics Recent leadership appointments to the board and a strong ethics/compliance function suggest emphasis on corporate governance and risk management. This can reassure potential partners and clients about compliance rigor in collaborations, enabling smoother complex deal structures and joint ventures in regulated markets.

Tech-enabled sales Adoption of analytics and cloud-based tech (Power BI, Google Cloud, Microsoft Azure, Adobe Experience Cloud) points to a data-driven sales approach. Opportunities exist to utilize analytics for market prioritization, payer strategy, and performance tracking to optimize partnerships, licensing deals, and regional market penetration.